Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy leads to adaptive immune resistance and displays resistance to PD-1/PD-L1 blockade in lung cancer, leading to less immune response of lung cancer patients. Tumor microenvironment (TME) is an integral tumor microenvironment, which is involved in immunotherapy resistance. Nanomedicine has been used to enhance the immunotherapy in lung cancer. In this review article, we described the association between TME and immunotherapy in lung cancer. We also highlighted the importance of TME in immunotherapy in lung cancer. Moreover, we discussed how nanoparticles are involved in regulation of TME to improve the efficacy of immunotherapy, including Nanomedicine SGT-53, AZD1080, Nanomodulator NRF2, Cisplatin nanoparticles, Au@PG, DPAICP@ME, SPIO NP@M-P, NBTXR3 nanoparticles, ARAC nanoparticles, Nano-DOX, MS NPs, Nab-paclitaxel, GNPs-hPD-L1 siRNA. Furthermore, we concluded that targeting TME by nanoparticles could be helpful to overcome resistance to PD-1/PD-L1 blockade in lung cancer.

 

Comments:

It sounds like your review article delves deep into the intricate relationship between the tumor microenvironment (TME), immune checkpoint inhibitor (ICI) therapy, and the role of nanomedicine in enhancing immunotherapy for lung cancer. The focus on overcoming resistance to PD-1/PD-L1 blockade through nanoparticle-mediated regulation of TME is particularly intriguing.

The exploration of various nanoparticle-based approaches, such as SGT-53, AZD1080, Nanomodulator NRF2, Cisplatin nanoparticles, and others, showcases the diverse strategies being investigated to modulate TME and improve the effectiveness of immunotherapy.

This comprehensive understanding of the TME's influence on immunotherapy resistance and the potential of nanoparticles to target and modify this environment seems promising for developing more effective treatments for lung cancer.

Are there any specific aspects or findings from your research that you find particularly noteworthy or exciting?

Related Products

Cat.No.	Product Name	Information
S7145	AZD1080	AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with Ki of 6.9 nM and 31 nM, respectively, shows >14-fold selectivity against CDK2, CDK5, CDK1 and Erk2.

Related Targets

GSK-3